Table 1.

Comparison of risk factors of 2 month sputum culture conversion between patients with isolates that had MIC above and below the CART analysis-derived susceptibility breakpoint (75 mg/L)

	MIC > breakpoint (n = 10)	MIC ≤ breakpoint (n = 48)	P value
Variable
age (years)	28.60 ± 10.22	31.10 ± 11.09	0.54
gender (% males)	70.00	62.50	0.73
HIV infection (%)	10.00	14.58	1.00
weight (kg)	51.29 ± 9.12	53.73 ± 7.98	0.22
chest X-ray cavities present (%)	100	89	1.00
time to positivity of culture at diagnosis (days)	10.78 ± 9.20	9.28 ± 4.40	0.56
Drug concentrations and AUCs
pyrazinamide AUC (mg · h/L)	429.90 ± 95.96	438.80 ± 140.10	0.91
pyrazinamide peak (mg/L)	34.85 ± 6.15	33.93 ± 8.78	0.51
rifampicin AUC (mg · h/L)	48.04 ± 20.87	51.62 ± 23.15	0.60
rifampicin peak (mg/L)	7.11 ± 1.88	7.50 ± 1.85	0.44
isoniazid AUC (mg · h/L)	12.79 ± 4.03	20.41 ± 13.81	0.13
isoniazid peak (mg/L)	2.71 ± 1.25	2.86 ± 1.86	0.94
ethambutol AUC (mg · h/L)	30.03 ± 11.33	34.38 ± 14.96	0.41
ethambutol peak (mg/L)	2.73 ± 0.84	3.060 ± 0.90	0.29